Skip to main content
Print Save

Atorvastatin / ezetimibe Side Effects

Medically reviewed by Drugs.com. Last updated on Jan 11, 2023.

Applies to atorvastatin / ezetimibe: oral tablet.

General

The more commonly reported adverse reactions have included increased ALT, increased AST, and musculoskeletal pain.[Ref]

Hepatic

Common (1% to 10%): ALT increased (5%), AST increased (4%)

Postmarketing reports: Hepatitis, cholelithiasis, cholecystitis, fatal and nonfatal hepatic failure[Ref]

Musculoskeletal

Common (1% to 10%): Musculoskeletal pain (3.8 to 4%), arthralgia (3 to 6.9%), pain in extremity (2.7 to 6%), myalgia (3.5%), muscle spasms (3%), muscle weakness (2%)

Postmarketing reports: Myopathy/rhabdomyolysis, necrotizing myopathy (rarely), injury, poisoning and procedural complication, tendon rupture, myositis[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea (4.1 to 6.8%), abdominal pain (3%), nausea (3 to 4%), dyspepsia (4.7%)[Ref]

Nervous system

Common (1% to 10%): Dizziness (2 to 6%), insomnia (3%), fatigue (2.4%)

Postmarketing reports: Headache, paraesthesia, peripheral neuropathy, amnesia, memory impairment, confusion, depression, dizziness[Ref]

Metabolic

Common (1% to 10%): Hyperkalemia (2%)[Ref]

Endocrine

Common (1% to 10%): Hot flushes (2%)[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection (5.7%)[Ref]

Hematologic

Postmarketing reports: Thrombocytopenia, elevated creatine phosphokinase[Ref]

Hypersensitivity

Postmarketing reports: Anaphylaxis, hypersensitivity reactions[Ref]

Immunologic

Common (1% to 10%): Influenza (2%)[Ref]

Respiratory

Common (1% to 10%): Coughing (2 to 3%), bronchitis (2%), sinusitis (2 to 2.8%), upper respiratory tract infection (4.3%), nasopharyngitis (up to 8.3%), pharyngolaryngeal pain (up to 2.3%)

Postmarketing reports: Interstitial lung disease[Ref]

Other

Postmarketing reports: Fatigue

Dermatologic

Postmarketing reports: Angioedema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rash, urticaria[Ref]

References

1. Cerner Multum, Inc. "Australian Product Information." O 0

2. "Product Information. Liptruzet (atorvastatin-ezetimibe)." Merck & Co., Inc (2013):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer